Cancer immunotherapy : immune suppression and tumor growth /

Saved in:

Bibliographic Details
Imprint:	Amsterdam ; Boston : Academic Press/Elsevier, ©2007.
Description:	1 online resource (xiii, 409 pages, 4 unnumbered pages of plates) : illustrations (some color)
Language:	English
Subject:	Cancer -- Immunotherapy. Antineoplastic agents -- Therapeutic use. Tumors -- Immunological aspects. Antineoplastic agents -- Therapeutic use. Cancer -- Immunotherapy. Tumors -- Immunological aspects. Neoplasms -- therapy. Immunotherapy -- methods. Electronic books.
Format:	E-Resource Book
URL for this record:	http://pi.lib.uchicago.edu/1001/cat/bib/11154120

Hidden Bibliographic Details
Other authors / contributors:	Prendergast, George C. Jaffee, Elizabeth M.
ISBN:	9780123725516 0123725518 9780080521855 0080521851
Notes:	Includes bibliographical references and index. Print version record.
Summary:	There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumoral immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational, and clinical cancer researchers an indispensable overview of immune escape as a critical trait in cancer and how applying specific combinations of immunotherapy and chemotherapy to attack this trait may radically improve the treatment of advanced disease. * Offers a synthesis of concepts that are useful to cancer immunologists and pharmacologists, who tend to work in disparate fields with little cross-communication * Drs Prendergast and Jaffee are internationally recognized leaders in cancer biology and immunology who have created a unique synthesis of fundamental and applied concepts in this important new area of cancer research * Summarizes the latest insights into how immune escape defines an essential trait of cancer * Includes numerous illustrations including: how molecular-targeted therapeutic drugs or traditional chemotherapy can be combined with immunotherapy to improve anti-tumor efficacy; and how reversing immune suppression by the tumor can cause tumor regression.
Other form:	Print version: Cancer immunotherapy. Amsterdam ; Boston : Academic Press/Elsevier, ©2007 9780123725516 0123725518

Table of Contents:

Contributors
Part I. Principles of Cancer Immunobiology
1. Introduction
I. Overview
II. Historical Background
III. Looking Ahead: Marrying Chemotherapy and Immunotherapy
IV. Parts of the Book
References
Further Reading
2. Cancer Immunoediting: From Immune Surveillance to Immune Escape
I. Introduction
II. Cancer Immune Surveillance
III. Cancer Immunoediting
IV. Concluding Remarks
References
3. Immunosurveillance: Innate and Adaptive Antitumor Immunity
I. Introduction
II. Innate Antitumor Responses
III. Innate Immune Cells
IV. Adaptive Antitumor Responses
V. The Interplay of Innate and Adaptive Antitumor Immunity
VI. Conclusion
References
4. Cytokine Regulation of Immune Tolerance to Tumors
I. Introduction
II. Cytokine Regulation of Immune Tolerance to Tumors
III. Summary and Future Perspectives
References
5. Immunological Sculpting: Natural Killer Cell Receptors and Ligands
I. Introduction
II. Activating Human NK Receptors
III. Inhibitory NK Receptors
IV. The Ly49 Receptor Family
V. Immunotherapy Approaches
VI. Conclusion
References
Further Reading
6. Immune Escape: Immunosuppressive Networks
I. Introduction
II. Imbalance Between Mature DCs and Immature DCs
III. Imbalance Between Stimulatory and Inhibitory B7 Family Molecules
IV. Imbalance Between Regulatory T Cells and Conventional T Cells
V. Concluding Remarks
References
Part II. Cancer Therapeutics
7. Cytotoxic Chemotherapy in Clinical Treatment of Cancer
I. Introduction
II. DNA-Damaging Agents
III. Antimetabolites
IV. Antimitotics
V. Chemotherapy Regimens
References
Useful Web Sites
8. Targeted Therapeutics in Cancer Treatment
I. Introduction
II. Cell Cycle
III. The MAPK Family
IV. Challenges in the Clinical Development of Signal Transduction Inhibitors
References
9. Concepts in Pharmacology and Toxicology
I. Introduction
II. Concepts in Pharmacokinetics
III. Concepts in Toxicology
IV. Clinical Concerns for Pharmacology and Safety
V. Conclusion
References
Further Reading
10. Cancer Immunotherapy: Challenges and Opportunities
I. Introduction
II. Prerequisites for Effective Cancer Immunotherapy: Identifying Tumor Antigens
III. Adoptive ("Passive") Immunotherapy
IV. Active-Specific Immunotherapy: Vaccines
V. Cancer-Induced Immunosuppression Impinges on Immunotherapy
VI. Cancer Immunotherapy in Mice Versus Humans
VII. Immunotherapy and Cancer Stem Cells
VIII. Autoimmunity Resulting from Cancer Immunotherapy
IX. Conclusion and Future Considerations
References
11. Cancer Vaccines
I. Introduction
II. Tumor Antigens
III. Spontaneous Immunity to Cancer
IV. Toleragenic Pressure on Immunity to Cancer
V. Immune Responses to Conventional Vaccines
VI. Cancer Vaccine Strategies
VII. DNA Vaccines
VIII. Challenges of Translation to the Clinic
IX. Concluding Remarks
References
Further Reading
Part III. Targets and Tactics to Improve Cancer Immunotherapy by Defeating Immune Suppression
12. Immunotherapy and Cancer Therapeutics: Why Partner?
I. Introduction: Why Immunotherapy for Cancer?
II. Immune Tolerance and Suppression: Multiple Layers of Negative Control
III. T Cell Activation: A Rheostat for Tuning Immune Responses
IV. Immune Modulation with Therapeutic Monoclonal Antibodies
V. Therapeutics that Mitigate the Influence of CD4[superscript +]CD25[superscript +] Tregs
VI. Endocrine and Biologically Targeted Therapy
VII. Conclusion
References
13. Immune Stimulatory Features of Classical Chemotherapy
I. Introduction
II. Tumor Cell Death
III. Pathways to Immunogenicity
IV. Chemotherapy and the Immune System
V. A Practical Partnership: Chemotherapy and Immunotherapy
VI. Effects of Chemotherapy on Human Antitumor Immunity and Chemoimmunotherapy Clinical Trials
References
14. Dendritic Cells and Coregulatory Signals: Immune Checkpoint Blockade to Stimulate Immunotherapy
I. Regulation of T Cell Responses to Antigen
II. Regulatory T Cells
III. Immune Checkpoints in the Tumor Microenvironment
IV. Monoclonal Antibodies that Interfere with Coinhibitory Receptors on T Cells
V. What Is the Most Effective Way to Use Checkpoint Inhibitors?
References
15. Regulatory T Cells in Tumor Immunity: Role of Toll-Like Receptors
I. Introduction
II. Immune Cells in Immunosurveillance and Tumor Destruction
III. TLRs and Their Signaling Pathways
IV. TLRs in Innate Immunity, Inflammation, and Cancer Development
V. Tumor-Infiltrating Immune Cells in the Tumor Microenvironment
VI. Molecular Marker for CD4[superscript +] Tregs
VII. Antigen Specificity of CD4[superscript +] Tregs
VIII. Suppressive Mechanisms of Tregs
IX. Functional Regulation of Tregs and Effector Cells by TLR Signaling
X. Implications for Enhancing Antitumor Immunity
XI. Conclusion
References
16. Tumor-Associated Macrophages in Cancer Growth and Progression
I. Introduction
II. Macrophage Polarization
III. Macrophage Recruitment at the Tumor Site
IV. Tam Expression of Selected M2 Protumoral Functions
V. Modulation of Adaptive Immunity by Tams
VI. Targeting Tams
VII. Concluding Remarks
References
17. Tumor-Associated Myeloid-Derived Suppressor Cells
I. Introduction
II. Multiple Suppressive Mechanisms that Contribute to Immunosuppression in Individuals with Tumors
III. MDSCs as a Key Cell Population that Mediates Tumor-Induced Immunosuppression
IV. MDSCs' Use of Mechanisms to Mediate Effects on Multiple Target Cells
V. MDSC Induction by Tumor-Derived Cytokines and Growth Factors
VI. MDSC Linking of Inflammation and Tumor Progression
VII. Agents Responsible for Reducing MDSC Levels
VIII. Conclusions: Implications for Immunotherapy
References
Further Reading
18. Programmed Death Ligand-1 and Galectin-1: Pieces in the Puzzle of Tumor-Immune Escape
I. Programmed Death Ligand 1 and Programmed Death 1 Interactions
II. Galectin 1
References
Further Reading
19. Indoleamine 2,3-Dioxygenase in Immune Escape: Regulation and Therapeutic Inhibition
I. Introduction
II. IDO Function in T Cell Regulation
III. Complex Control of IDO by Immune Regulatory Factors
IV. Immune Tolerance Via IDO in Dendritic Cells
V. IDO Dysregulation in Cancer Cells
VI. IDO as a Target for Therapeutic Intervention
VII. Discovery and Development of IDO Inhibitors
VIII. Conclusion
References
Further Reading
20. Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-Arginine Metabolism in Immune Modulation
I. Introduction
II. NOS: Genes, Regulation, and Activity
III. ARG: Genes, Regulation, and Activity
IV. Immunoregulatory Activities of ARG and NOS
V. Possible Physiological Role for L-ARG Metabolism in Immunity Control
VI. NOS in Cancer
VII. ARG in Cancer
VIII. ARG and NOS Inhibitors: A Novel Class of Immune Adjuvants?
IX. Conclusion and Perspectives
References
Further Reading
Index

Cancer immunotherapy : immune suppression and tumor growth /

Similar Items